Connect with us

Fintech PR

Trintech Fuels Strategic Growth with Four Executive Hires, Deepening Subject Matter Expertise

Published

on

trintech-fuels-strategic-growth-with-four-executive-hires,-deepening-subject-matter-expertise

Trintech Announces Newly Appointed CMO, CTO, SVP, General Counsel and Managing Director, EMEA

DALLAS, Sept. 7, 2023 /PRNewswire/ — Trintech, a leading global provider of cloud-based reconciliation and financial close solutions, today announced the appointment of Tamir Sigal as Chief Marketing Officer, Sunil Padiyar as Chief Technology Officer, Heather Randall as SVP, General Counsel and Scott Vipond as Managing Director, EMEA.

“I am thrilled to announce the newest additions to Trintech’s Executive Leadership team,” said Darren Heffernan, CEO of Trintech. “We find ourselves at a very exciting and pivotal time at Trintech focused on scaling our business, as we just announced our recent acquisition of Fiserv’s Reconciliation Business a few weeks ago, and continuing to drive our core strategy of helping organizations of all sizes simplify and transform their accounting and finance processes. Each one of these executives will have an integral part in continuing that momentum as they join a highly experienced management team with a proven track record and ability to drive ongoing success.”

As Chief Marketing Officer, Sigal will be responsible for leading Trintech’s global marketing functions, including marketing strategy, brand development, digital experience, product marketing and customer engagement. “Our global marketing organization will benefit greatly from the leadership of Tamir, as he has over 25 years of experience in B2B software for the enterprise and small-medium business (SMB) markets. I am confident that his contributions will enhance Trintech’s market presence, customer loyalty, and overall brand success,” said Heffernan. Prior to Trintech, Sigal led global marketing teams for Mobius, ArisGlobal, RSD and most recently served as Chief Marketing Officer for Quadient.

Leading the company’s global R&D team, Padiyar will play a critical role in ensuring that Trintech continues to stay at the forefront of product innovation and that Trintech customers realize the total business value of its solutions. “Under Sunil’s leadership, we are aligning our engineering efforts and capabilities to better deliver innovative cloud-based solutions to our global customer base,” continued Heffernan. Padiyar is a seasoned CTO with a robust track record in architecting cloud-based B2B SaaS solutions for rapidly growing software enterprises. Prior to Trintech, Padiyar served as CTO of Corcentric.

As SVP, General Counsel, Randall will be responsible for overseeing and managing all legal matters for Trintech, including legal guidance, strategic advice, and ensuring compliance with relevant laws and regulations. “Heather brings 20+ years of corporate legal experience representing public and private companies and overseeing their business legal affairs, including commercial contracts and transactions, information security, and compliance,” said Heffernan. “Heather will play a critical role in managing Trintech’s legal interests while enabling our growth.” Prior to Trintech, Randall most recently served as Vice President, Legal at DIRECTV.

As Managing Director, EMEA, Vipond will be focused on leading Trintech’s European business by driving greater cross-functional collaboration, identifying in-region strategic customer opportunities, and aligning efforts in EMEA to Trintech’s overall corporate vision. “I have had the privilege of working with Scott for 10+ years, and I cannot think of a more qualified person for this role,” said Heffernan. Prior to becoming Managing Director, EMEA, Scott served as VP, Customer Success, where he led our customer-facing teams in Europe, including Customer Success, Professional Services and Support, and helped to drive Partner Delivery Enablement across the region. He is a CIMA-qualified Accountant with over 20 years of experience in software delivery and is an expert in driving financial and commercial performance for global organizations. 

About Trintech

Trintech, a leading global provider of cloud-based, integrated reconciliation and financial close solutions for Finance & Accounting departments. From high volume transaction matching, to automating and managing balance sheet reconciliations, intercompany accounting, journal entries, close management tasks, to governance, risk and compliance – Trintech’s portfolio of financial solutions, including its Cadency Platform (for large enterprises) and Adra Suite (for mid-market organizations), help manage all aspects of the reconciliation and financial close processes. Trintech’s excellence in both innovation and client support have been recognized with a variety of awards over the years including most recently “Easiest to Do Business With” and “Fastest Implementation” in G2’s Fall Report. Over 4,200 clients worldwide – including the majority of the Fortune 100 – rely on Trintech’s solutions to enable their F&A operation to become a strategic partner to the business by optimizing data, controlling risk, driving efficiencies, and providing strategic insights.

Headquartered in Plano, Texas, Trintech has offices located across the United States, United Kingdom, Australia, Singapore, France, Germany, Ireland, the Netherlands, and the Nordics, as well as strategic partners in South Africa, Latin America, and the Asia Pacific. To learn more about Trintech, visit www.trintech.com or connect with us on LinkedInFacebookTwitter and Instagram.

Trintech Media Contact:
Kelli Shoevlin
Director, Global Corporate Marketing & Communications
[email protected] 

Trintech Logo

Photo – https://mma.prnewswire.com/media/2203523/Trintech_Executive_Hires.jpg
Logo – https://mma.prnewswire.com/media/2161503/Trintech_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/trintech-fuels-strategic-growth-with-four-executive-hires-deepening-subject-matter-expertise-301919821.html

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Fintech PR

The Office of the Executive Committee of the WMC Released the List of “Top 500 Chinese Manufacturing Enterprises in 2023”

Published

on

the-office-of-the-executive-committee-of-the-wmc-released-the-list-of-“top-500-chinese-manufacturing-enterprises-in-2023”

HEFEI, China, Sept. 22, 2023 /PRNewswire/ — The 2023 World Manufacturing Convention (WMC) was opened on September 20 in Hefei, Anhui Province, China. In the convention, the list of “Top 500 Chinese Manufacturing Enterprises in 2023” was released, indicating that the operating revenue of China’s top 500 manufacturing enterprises in 2023 has exceeded 50 trillion RMB for the first time, reaching 51.06 trillion RMB, which was an increase of 8.38%.

Among the top 500 manufacturing enterprises, the heavy chemical industry still occupies the main position, and four out of the five industries with the largest operating revenue belong to the heavy chemical industries. Meanwhile, the pace of development of strategic emerging industries has accelerated, and most of the enterprises with the top operating revenue and net profit growth are strategic emerging industry enterprises. The top five industry’s average revenue growth rates are from power batteries and energy storage batteries, wind energy, solar equipment manufacturing, medical equipment manufacturing, computer and office equipment and chemical fiber manufacturing, of which the top three growth rate reached more than 45%, respectively 59.72%, 49.42%, 45.54%. According to the analysis of the ranking, the total R&D expenses of China’s top 500 manufacturing enterprises in 2023 have reached 109.6215 billion RMB, which was an increase of 3.83% over the previous year; the R&D intensity was 2.33%, which is at a high level in recent years. The average R&D expenses of industries such as aerospace, communication equipment manufacturing, railway traffic equipment manufacturing, textile printing and dyeing are at the forefront from the perspective of various industries.

The “2023 Development Report on Anhui Manufacturing” prepared by the Anhui Provincial Department of Economy and Information Technology was also released on the day of the convention. The report shows that the average annual growth rate of industrial value added of enterprises above the designated size in Anhui Province was 9.5% from 2012 to 2022, ranking the first in the central region, the first in the Yangtze River Delta and the fourth in whole China. In 2022, the province’s industrial enterprises above the designated size have achieved an operating revenue of 4.9 trillion RMB, ranking 10th in the country. Among them, manufacturing enterprises above the designated size have achieved an operating revenue of 4.4 trillion RMB; the added value of the manufacturing industry has exceeded 1 trillion RMB, accounting for 26.5% of GDP, which was an increase of 0.3 percentage points over the previous year.

In recent years, Anhui’s manufacturing industry has accelerated the development of integrated clustering, especially the clustering of advanced manufacturing chains, forming an unformidable trend. The top one industry is “automobile” with irresistible force, while the PV and energy storage gathering “sparkling light” into a raging torch, the IC industry showing its brilliant “core”, the new “displays and screens” experiencing a rapid boom, and the AI “valley” astonishing the world. A number of industrial landmarks have become an important force leading the trend of China’s and even the world’s manufacturing industry.

Contact: Yuan Fan
Tel: 0086- 13552640063
E-mail: [email protected] 

Photo – https://mma.prnewswire.com/media/2218768/World_Manufacturing_Convention.jpg
Logo – https://mma.prnewswire.com/media/2218767/World_Manufacturing_Convention_Logo.jpg

World Manufacturing Convention Logo

Cision View original content:https://www.prnewswire.co.uk/news-releases/the-office-of-the-executive-committee-of-the-wmc-released-the-list-of-top-500-chinese-manufacturing-enterprises-in-2023-301936299.html

Continue Reading

Fintech PR

Asian International Arbitration Centre and SOAS University of London, Arbitration and Dispute Resolution Centre sign MoU to promote best practice in arbitration

Published

on

asian-international-arbitration-centre-and-soas-university-of-london,-arbitration-and-dispute-resolution-centre-sign-mou-to-promote-best-practice-in-arbitration

LONDON, Sept. 22, 2023 /PRNewswire/ — The Asian International Arbitration Centre (AIAC), Kuala Lumpur, and SOAS University of London, Arbitration and Dispute Resolution Centre (SADRC) have yesterday (Thursday 21 September) signed a Memorandum of Understanding to advance collaboration and promote best practice in alternative dispute resolution techniques, including arbitration.

The MoU will see the AIAC and SADRC further develop teaching and research activities in alternative dispute resolution in line with international best practice, to coordinate efforts to promote the use of alternative dispute resolution.

Azalina Othman Said, Malaysia’s Minister of Law and Institutional Reform, was in London to attend the MoU signing, and offer it Malaysia’s full support to increase dialogue in arbitration. The Minister attend the MoU signing alongside Malaysia’s High Commissioner to the UK Dato’ Zakri Jaafar, Solicitor General II of the Attorney General’s Chambers of Malaysia, Datuk Almalena Sharmila binti Dato’ Dr. Johan, and Deputy Director General of the Legal Affairs Division of the Prime Minister’s Department, Dr. Punitha Silivarajoo. The Head of Legal Services Trade and Promotion at the UK Ministry of Justice, Holly O’Callaghan, attended to offer the UK Government’s support.

Speaking about the MoU signing, Emilia Onyema, Professor of International Commercial law, SOAS & Director, SADRC, said:

“At the SADRC, we are proud that today we have become a partner of the Asian International Arbitration Centre. Through signing this MoU, we hope to promote alternative dispute resolution techniques in our SOAS regions, Asia, Middle East and Africa, and particularly Malaysia, and learn from our shared experiences.”

Sundra Rajoo, Director of AIAC, said:

 “We are delighted that today, the Asian International Arbitration Centre has formally agreed a MoU with SOAS University of London’s prestigious new Arbitration and Dispute Resolution Centre. The formalization of the MoU between both institutions is indeed a remarkable and significant achievement. We firmly believe that through this innovative partnership, we can enhance our joint efforts to promote best practices in alternative dispute resolution, benefiting not only the UK and Malaysia but also the broader Asian and African region.”

Azalina Othman Said, Malaysia’s Minister of Law and Institutional Reform, said:

”The UK and Malaysia have a long shared history of collaborating to tackle mutual challenges, and the signing of the MoU between the Asian International Arbitration Centre and SOAS University of London’s Arbitration and Dispute Resolution Centre underscores the depth of our relationship and our commitment to advancing global best practices in arbitration.”

In practical terms, this collaboration would include steps to encourage, enhance and promote the following areas of cooperation:

  • Joint courses and training;
  • Joint research programmes;
  • Contribution of expertise – such as researchers, panellists, speakers and guest lecturers – to initiatives which share common goals;
  • Publication of academic journals, books and newsletters;
  • Student internship programmes;
  • Organising or hosting joint conferences, workshops, seminars and forums.

In addition to arbitration, the two centres have committed to also promote Islamic arbitration, sports arbitration, mediation, adjudication, and domain name dispute resolution as alternative dispute resolution methods.

The MoU signing comes ahead of the inaugural London International Arbitration Colloquium, which will take place on Monday 25 September at the International Dispute Resolution Centre in London, to consider the role of international arbitration involving sovereign states.

Over the course of three panel sessions, guests will hear expert insights on jurisdictional challenges in investment arbitration, the impact of investment claims on states and their sovereignty, and the role of third-party funding in access to justice.

Contact

For more information, contact:

 

 

View original content:https://www.prnewswire.co.uk/news-releases/asian-international-arbitration-centre-and-soas-university-of-london-arbitration-and-dispute-resolution-centre-sign-mou-to-promote-best-practice-in-arbitration-301936275.html

Continue Reading

Fintech PR

Revolutionary Cancer Treatment Advances Promise Brighter Future Amid Federal Funding Uncertainty

Published

on

revolutionary-cancer-treatment-advances-promise-brighter-future-amid-federal-funding-uncertainty

FN Media Group Presents USA News Group News Commentary

VANCOUVER, British Columbia, Sept. 22, 2023 /PRNewswire/ — USA News Group – Despite the potential federal funding challenges due to the recent debt ceiling deal, optimism in the battle against cancer persists, thanks in large part to the audacious “Cancer Moonshot” initiative. This ambitious plan, aimed at halving cancer rates within the next quarter-century, continues to fuel hope even as concerns about the stability of National Institutes of Health (NIH) funding arise. In these turbulent times, the resilience and ingenuity of the biotech sector provide a beacon of hope. For instance, Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Zymeworks Inc. (NASDAQ: ZYME), Jazz Pharmaceuticals plc (NASDAQ: JAZZ), Protagonist Therapeutics, Inc. (NASDAQ: PTGX), and Amgen Inc. (NASDAQ: AMGN), have each demonstrated inspiring progress and unwavering commitment in advancing cancer treatments, highlighting their vital role in the future of cancer therapy.

At the 2023 ASCO Annual Meeting Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) shared exciting results from its important study, called BRACELET-1, with results that caught the eye of RBC Capital. The oral presentation shared at the event described how they’ve been testing a treatment for advanced breast cancer, and it’s looking very promising.

The treatment combines Oncolytics’ flagship drug, pelareorep, with a well-known cancer medicine, paclitaxel. Pelareorep is a unique drug that targets and kills cancer cells by making them self-destruct while leaving healthy cells unharmed. The results of BRACELET-1 showed that this mixture could slow down the cancer significantly. It even lowered the risk of the cancer getting worse by a significant 71% compared to just using paclitaxel.

For people battling cancer, this means more quality time before the cancer might get worse. Specifically, people getting the combined treatment had about 9.5 good months before the disease advanced, compared to just 6.3 months with only paclitaxel.

Moreover, the new treatment was better at shrinking or even eliminating the cancer. An impressive 37.5% of patients responded to the combined treatment, as opposed to just 13.3% with paclitaxel alone.

“BRACELET-1’s positive results complement prior phase 2 data showing a statistically significant increase in overall survival when pelareorep was combined with paclitaxel by demonstrating similar robust improvements in PFS and ORR in less heavily pre-treated patients,” said Dr. Matt Coffey, President and CEO of Oncolytics Biotech. “Given this exciting finding, our next step is to discuss our data with the FDA to investigate incorporating dual PFS and OS endpoints into our breast cancer program’s registrational study. Including a PFS endpoint will substantially reduce the time to a pivotal readout from the registrational trial, thereby accelerating pelareorep’s path to potential approval as we work to address the urgent needs of HR+/HER2- breast cancer patients.”  

Following these encouraging results, Oncolytics Biotech is now ready to take the next steps in advancing its breast cancer program. They’re planning to talk to the FDA and push forward with more registrational studies, having already received Fast Track Designation for pelareorep in the treatment of advanced/metastatic pancreatic cancer, in late 2022. This could make pelareorep an approved treatment for breast cancer sooner than expected.

Another highlight from the ASCO presentations was that of Jazz Pharmaceuticals plc (NASDAQ: JAZZ) and Zymeworks Inc. (NASDAQ: ZYME). Together the two companies presented promising data from a pivotal Phase 2b trial, evaluating the bispecific antibody, zanidatamab, in HER2-amplified biliary tract cancers (BTC), a particularly aggressive group of cancers that currently lack HER2-targeted treatment options.

The results were not only presented at ASCO but also concurrently published in The Lancet Oncology. They demonstrated meaningful clinical benefit, including antitumor activity, a confirmed objective response rate (cORR) of 41.3%, a median duration of response (DOR) of 12.9 months, and a median progression-free survival (PFS) of 5.5 months.

“The HERIZON-BTC-01 trial advances an exciting field of oncology research where we can leverage next-generation sequencing on BTC patients to understand genomic markers of the disease and choose the appropriate targeted therapies for these patients,” said Shubham Pant, M.D., professor of Gastrointestinal Medical Oncology and Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center.

The data clearly outshines current chemotherapy treatments for BTC, which offer only a 5 to 15 percent ORR and median PFS of 1.4 to 4 months. The Zymeworks-Jazz partnership showcased an oral presentation on the pivotal HERIZON-BTC-01 study results demonstrating zanidatamab’s meaningful clinical benefit and tolerable safety profile in patients with HER2-amplified BTC.

Zanidatamab has already been granted Breakthrough Therapy designation and two Fast Track designations by the FDA, making it an exciting contender in the fight against these tough-to-treat cancers. These exciting results suggest a potential future where targeted treatments like zanidatamab transform the lives of patients in critical need.

With three oral presentations and two poster discussions, and over 25 abstracts, Amgen’s (NASDAQ: AMGN) presence at ASCO included new scientific and clinical research across its diverse oncology portfolio and pipeline, featuring data in hard-to-treat tumor types like non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and small cell lung cancer (SCLC).

“Our presentations at ASCO… illustrate how we’re advancing novel approaches to address the toughest thoracic and colorectal cancers with limited treatment options,” said David M. Reese, M.D., executive vice president of Research and Development at Amgen. “We’re focused on expanding the reach and impact of our transformative, first-in-class medicines to help more people living with cancer.”  

Highlights from Amgen’s presentations included data on LUMAKRAS® (sotorasib) from the first study evaluating its intracranial efficacy as a KRAS G12C inhibitor versus docetaxel in treated KRAS G12C-mutated advanced NSCLC. Additional analyses from DeLLphi-300 highlighted the safety and clinical efficacy of Tarlatamab, an investigational first-in-class BiTE® immunotherapy, in patients with SCLC with treated and stable brain metastases. Other studies presented novel combinations showing encouraging safety and efficacy in pre-treated KRAS G12C-mutated metastatic CRC and first-line NSCLC.

These presentations showed advances in several therapeutic areas, including hematologic malignancies, melanoma/skin cancers, and gastrointestinal cancers. Some of the key clinical studies presented include the IKEMA study for KYPROLIS®, the PARADIGM trial for VECTIBIX®, and a phase 2 study on IMLYGIC® in advanced sarcoma.

One company also potentially (yet indirectly) making significant strides in the oncology sector is Protagonist Therapeutics, Inc. (NASDAQ: PTGX), a Newark, California-based biopharmaceutical firm. Although not traditionally labeled as a cancer biotech firm, their innovative approach towards blood disorders, notably Polycythemia Vera, a slow-growing blood cancer, underscores their contribution to the broader oncology landscape.

Protagonist’s leading drug candidate, rusfertide (PTG-300), is currently under the microscope. The company recently announced that additional data from the REVIVE study of rusfertide in polycythemia vera would be presented at the annual Congress of the European Hematology Association (EHA). This study holds immense promise as it explores the ability of rusfertide to improve symptoms related to this blood disorder.

The Moffitt Cancer Center and the Department of Malignant Hematology have taken a keen interest in this study, suggesting rusfertide’s potential broader application in the field of hematology and possibly in other forms of cancer. An assistant member of the Department, Dr. Andrew Kuykendall, will present the study results, further demonstrating the deep links between Protagonist’s work and oncology professionals.

Moreover, Protagonist is also advancing their peptide-based new chemical entity, JNJ-2113 (formerly PN-235), which recently showed positive topline results in treating moderate-to-severe plaque psoriasis. While psoriasis is not a form of cancer, the advancement of these biological drugs signals a new direction in treating various human conditions, including cancers.

Article Source: https://usanewsgroup.com/2023/05/31/could-this-company-be-on-track-to-cure-pancreatic-and-breast-cancer-2/ 

Article Source:
USA News Group
http://USAnewsgroup.com 
[email protected]

DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles.

While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

USA News Group is Source of all content listed above. FN Media Group, LLC (FNM), is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with USA News Group or any company mentioned herein. The commentary, views and opinions expressed in this release by USA News Group are solely those of USA News Group and are not shared by and do not reflect in any manner the views or opinions of FNM. FNM is not liable for any investment decisions by its readers or subscribers. FNM and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM was not compensated by any public company mentioned herein to disseminate this press release.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.

Media Contact Information:
FN Media Group, LLC
Media Contact e-mail:  
[email protected] 
U.S. Phone: +1(954)345-0611

View original content:https://www.prnewswire.co.uk/news-releases/revolutionary-cancer-treatment-advances-promise-brighter-future-amid-federal-funding-uncertainty-301936242.html

Continue Reading
Advertisement

Latest news

Trending